Najmeh Davoodian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Najmeh Davoodian has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Alain Gerald Bertoni
Wake Forest University School of Medicine, Winston-Salem, NC, USA
2 shared publications - Amir Baniasad
Lung Disease Research Center Mashhad University of Medical Sciences Mashhad Iran
2 shared publications - Crystal Man Ying Lee
School of Population Health, Curtin University, Perth, Australia
2 shared publications - Davood Khalili
Prevention of Metabolic Disorders Research Center, Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Dianna Josephine Magliano
Baker Heart and Diabetes Institute, Melbourne, Australia
2 shared publications - Edward W. Gregg
School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland
2 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 145, 106191
Associations of the triglyceride-glucose index and its obesity-related derivative with all-cause mortality, cardiovascular events, and long-term survival and functioning in older adults
- 23 February 2026
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 145, 106191
Open AccessAssociations of the triglyceride-glucose index and its obesity-related derivative with all-cause mortality, cardiovascular events, and long-term survival and functioning in older adults
- 12 December 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (2) , 531-532
Impact of normoglycaemia and prediabetes definitions on the estimated benefits of regression from prediabetes to normoglycaemia for type 2 diabetes risk. Reply to Choi W [Letter]
- 12 December 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (2) , 531-532
Impact of normoglycaemia and prediabetes definitions on the estimated benefits of regression from prediabetes to normoglycaemia for type 2 diabetes risk. Reply to Choi W [Letter]
- Open Access
- 18 October 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (1) , 69-80
Regression from prediabetes to normoglycaemia and the role of cardiometabolic risk factors on the subsequent risk of developing type 2 diabetes
Aims/hypothesis: We aimed to investigate the association between reversion to normoglycaemia among individuals with prediabetes (fasting plasma glucose 5.6–6.9 mmol/l in the absence of other criteria for type 2 diabetes) and the subsequent risk of type 2 diabetes, and to examine whether concurrent favourable cardiometabolic risk factor profiles modify this association. Methods: We used individual-level data from prospective cohorts in the USA, Australia and Asia. Participants with prediabetes at baseline, with at least two follow-ups ( n =8191) at median intervals of 2.9 years (IQR 2.3–9.0) and 3.1 years (IQR 2.6–3.6), were classified into restoration of normoglycaemia and persistent prediabetes groups based on the glucose status at the first follow-up (normoglycaemia or prediabetes). Type 2 diabetes occurrence was assessed at subsequent follow-ups. Hierarchical mixed-effects proportional hazards Weibull models estimated type 2 diabetes risk, adjusting for age, sex and cardiometabolic risk factors. A subgroup analysis evaluated the combined association of normoglycaemia restoration and normal cardiometabolic risk factor levels on subsequent type 2 diabetes risk. Results: In individuals with prediabetes, normoglycaemia restoration compared with persistent prediabetes was associated with a 51% lower risk of developing type 2 diabetes. Even lower risks were observed among individuals with concurrent favourable cardiometabolic profiles, including non-smokers (HR 0.20, 95% CI 0.10, 0.31), and those with normal BMI (0.16, 95% CI 0.06, 0.27), waist circumference (0.22, 95% CI 0.12, 0.33), waist-to-height ratio (0.15, 95% CI 0.03, 0.26), WHR (0.17, 95% CI 0.05, 0.28), and systolic (0.20, 95% CI 0.11, 0.30) and diastolic (0.25, 95% CI 0.12, 0.38) blood pressure, triacylglycerol (0.24, 95% CI 0.13, 0.35) and HDL-cholesterol levels (0.21, 95% CI 0.13, 0.29). Weight loss combined with normoglycaemia restoration was also associated with lower type 2 diabetes risk (0.18, 95% CI 0.07, 0.30) compared with weight gain and persistent prediabetes. Conclusions/interpretation: Our results suggest that prioritising normoglycaemia restoration during the prediabetes stage in clinical guidelines may contribute to reducing the risk of type 2 diabetes, particularly when accompanied by favourable cardiometabolic health profiles. Graphical
- 18 October 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (1) , 69-80
Open AccessRegression from prediabetes to normoglycaemia and the role of cardiometabolic risk factors on the subsequent risk of developing type 2 diabetes
Aims/hypothesis: We aimed to investigate the association between reversion to normoglycaemia among individuals with prediabetes (fasting plasma glucose 5.6–6.9 mmol/l in the absence of other criteria for type 2 diabetes) and the subsequent risk of type 2 diabetes, and to examine whether concurrent favourable cardiometabolic risk factor profiles modify this association. Methods: We used individual-level data from prospective cohorts in the USA, Australia and Asia. Participants with prediabetes at baseline, with at least two follow-ups ( n =8191) at median intervals of 2.9 years (IQR 2.3–9.0) and 3.1 years (IQR 2.6–3.6), were classified into restoration of normoglycaemia and persistent prediabetes groups based on the glucose status at the first follow-up (normoglycaemia or prediabetes). Type 2 diabetes occurrence was assessed at subsequent follow-ups. Hierarchical mixed-effects proportional hazards Weibull models estimated type 2 diabetes risk, adjusting for age, sex and cardiometabolic risk factors. A subgroup analysis evaluated the combined association of normoglycaemia restoration and normal cardiometabolic risk factor levels on subsequent type 2 diabetes risk. Results: In individuals with prediabetes, normoglycaemia restoration compared with persistent prediabetes was associated with a 51% lower risk of developing type 2 diabetes. Even lower risks were observed among individuals with concurrent favourable cardiometabolic profiles, including non-smokers (HR 0.20, 95% CI 0.10, 0.31), and those with normal BMI (0.16, 95% CI 0.06, 0.27), waist circumference (0.22, 95% CI 0.12, 0.33), waist-to-height ratio (0.15, 95% CI 0.03, 0.26), WHR (0.17, 95% CI 0.05, 0.28), and systolic (0.20, 95% CI 0.11, 0.30) and diastolic (0.25, 95% CI 0.12, 0.38) blood pressure, triacylglycerol (0.24, 95% CI 0.13, 0.35) and HDL-cholesterol levels (0.21, 95% CI 0.13, 0.29). Weight loss combined with normoglycaemia restoration was also associated with lower type 2 diabetes risk (0.18, 95% CI 0.07, 0.30) compared with weight gain and persistent prediabetes. Conclusions/interpretation: Our results suggest that prioritising normoglycaemia restoration during the prediabetes stage in clinical guidelines may contribute to reducing the risk of type 2 diabetes, particularly when accompanied by favourable cardiometabolic health profiles. Graphical
- 8 March 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (1) , 1-14
Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension
Introduction Patients with pulmonary hypertension (PH) often have comorbid sleep apnea (SA), but the prevalence, severity, and clinical characteristics of PH patients with SA have not been well studied. Methods Using a combination of the keywords “pulmonary hypertension” and “sleep apnea,” the PubMed, Embase, Web of Science, and Scopus databases were searched for articles reporting the prevalence, severity, and clinical characteristics of PH patients with SA that were available through June 25, 2024. Results Of the 7969 studies, 39 were included in the final analysis. Prevalence of obstructive and central SA was 45.4% [39.2%, 51.6%]) and 9.3% [6%, 14.2%], respectively. The mean apnea hypopnea index (AHI) of patients with obstructive SA and PH was 18 [13.6, 22.4] with a standard error of 2.2. Subgroup analysis revealed that 51.4% [38.4%, 64.2%] had mild SA, 28% [22.5%, 33.6%] had moderate, and 20% [15.2%, 25%] had severe SA. PH patients with SA were characterized by male sex (odds ratio (OR) = 1.86 [1.45, 2.37], P < 0.001), older age (mean difference (MD) = -9.37 [-14.23, -4.43], P < 0.001), and higher body mass index (BMI) (MD = -2.16 [-3.32, -1.00], P < 0.001) compared to those without SA. However, mean pulmonary arterial pressure (mPAP) was not significantly different between SA and non-SA (MD = -2.4 [-5.1, 0.3], P = 0.078). Meta-regression showed no significant association between mPAP and AHI among patients with PH and SA (P = 0.13). Conclusion Our study found that SA is common in PH patients with certain clinical characteristics. We recommend conducting sleep studies in all PH patients, especially in older, overweight male patients.
- 8 March 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (1) , 1-14
Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension
Introduction Patients with pulmonary hypertension (PH) often have comorbid sleep apnea (SA), but the prevalence, severity, and clinical characteristics of PH patients with SA have not been well studied. Methods Using a combination of the keywords “pulmonary hypertension” and “sleep apnea,” the PubMed, Embase, Web of Science, and Scopus databases were searched for articles reporting the prevalence, severity, and clinical characteristics of PH patients with SA that were available through June 25, 2024. Results Of the 7969 studies, 39 were included in the final analysis. Prevalence of obstructive and central SA was 45.4% [39.2%, 51.6%]) and 9.3% [6%, 14.2%], respectively. The mean apnea hypopnea index (AHI) of patients with obstructive SA and PH was 18 [13.6, 22.4] with a standard error of 2.2. Subgroup analysis revealed that 51.4% [38.4%, 64.2%] had mild SA, 28% [22.5%, 33.6%] had moderate, and 20% [15.2%, 25%] had severe SA. PH patients with SA were characterized by male sex (odds ratio (OR) = 1.86 [1.45, 2.37], P < 0.001), older age (mean difference (MD) = -9.37 [-14.23, -4.43], P < 0.001), and higher body mass index (BMI) (MD = -2.16 [-3.32, -1.00], P < 0.001) compared to those without SA. However, mean pulmonary arterial pressure (mPAP) was not significantly different between SA and non-SA (MD = -2.4 [-5.1, 0.3], P = 0.078). Meta-regression showed no significant association between mPAP and AHI among patients with PH and SA (P = 0.13). Conclusion Our study found that SA is common in PH patients with certain clinical characteristics. We recommend conducting sleep studies in all PH patients, especially in older, overweight male patients.
- Open Access
- 22 April 2022
- Published by Wiley in Brain and Behavior
- Vol. 12 (5) , e2596
Personality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: A cross‐sectional case–control study
Objective: Multiple sclerosis is a chronic demyelinating disease of the central nervous system that can cause severe disability and impair the quality of life (QoL).Methods: In the current cross‐sectional, case–control study, we investigated personality traits, anxiety and depression levels, in 101 patients in the case group and 202 individuals as a control group. The personality traits of the participants were collected via the Neuroticism‐Extraversion‐Openness Five‐Factor Inventory (NEO‐FFI) questionnaire. We evaluated the level of anxiety and depression based on the Hospital Anxiety and Depression Scale questionnaire.Results: Our study showed in patients with disease duration above 1 year, the rates of agreement (29.78), anxiety (8.83), and depression level (6.39) were significantly higher than the control group (27.19, 6.47, and 4.97, respectively). Although patients with disease duration below 1 year showed a higher level of agreement and conscientiousness (29.65 and 34.35, respectively) than controls (26.6 and 30.86, respectively). The level of anxiety and depression in patients with a disability index above 4.5 was significantly higher than patients with a disability index below 1. Patients with a disability index below 1 showed a higher rate of extraversion and agreement and conscientiousness (31.47, 31.53, and 35.07, respectively) than controls (25.5, 26.23, and 3033, respectively). In addition, patients with a disability index above 4.5 showed a higher level of agreement (35.64), conscientiousness (35.5), anxiety (9.64), and depression (7.5) than controls (25.96, 30.71, 6.96, and 4.71, respectively).Conclusions: In conclusion, anxiety and depression levels were much higher among MS patients compared with controls and the severity of these conditions correlate with the score of the disability index. Therefore, a complete comprehension of these conditions by the neurologist could be vital in improving patients’ QoL and increasing compliance and adherence to pharmacological therapy.
- 22 April 2022
- Published by Wiley in Brain and Behavior
- Vol. 12 (5) , e2596
Open AccessPersonality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: A cross‐sectional case–control study
Objective: Multiple sclerosis is a chronic demyelinating disease of the central nervous system that can cause severe disability and impair the quality of life (QoL).Methods: In the current cross‐sectional, case–control study, we investigated personality traits, anxiety and depression levels, in 101 patients in the case group and 202 individuals as a control group. The personality traits of the participants were collected via the Neuroticism‐Extraversion‐Openness Five‐Factor Inventory (NEO‐FFI) questionnaire. We evaluated the level of anxiety and depression based on the Hospital Anxiety and Depression Scale questionnaire.Results: Our study showed in patients with disease duration above 1 year, the rates of agreement (29.78), anxiety (8.83), and depression level (6.39) were significantly higher than the control group (27.19, 6.47, and 4.97, respectively). Although patients with disease duration below 1 year showed a higher level of agreement and conscientiousness (29.65 and 34.35, respectively) than controls (26.6 and 30.86, respectively). The level of anxiety and depression in patients with a disability index above 4.5 was significantly higher than patients with a disability index below 1. Patients with a disability index below 1 showed a higher rate of extraversion and agreement and conscientiousness (31.47, 31.53, and 35.07, respectively) than controls (25.5, 26.23, and 3033, respectively). In addition, patients with a disability index above 4.5 showed a higher level of agreement (35.64), conscientiousness (35.5), anxiety (9.64), and depression (7.5) than controls (25.96, 30.71, 6.96, and 4.71, respectively).Conclusions: In conclusion, anxiety and depression levels were much higher among MS patients compared with controls and the severity of these conditions correlate with the score of the disability index. Therefore, a complete comprehension of these conditions by the neurologist could be vital in improving patients’ QoL and increasing compliance and adherence to pharmacological therapy.
- Open Access
- 19 November 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (11) , e05096
The first presentation of Wolcott‐Rallison syndrome in a four‐month‐old infant with diabetic ketoacidosis (DKA) precipitating by COVID‐19: A case report
Monogenic diabetes mellitus (eg, Wolcott‐Rallison syndrome) is a rare condition. It associates with neonatal or early‐infancy insulin‐dependent diabetes. We reported DKA in the four‐month infant as the first presentation of monogenic diabetes that has accelerated by COVID‐19 infection. Therefore, considering the concurrency of COVID‐19 and DKA is crucial.
- 19 November 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (11) , e05096
Open AccessThe first presentation of Wolcott‐Rallison syndrome in a four‐month‐old infant with diabetic ketoacidosis (DKA) precipitating by COVID‐19: A case report
Monogenic diabetes mellitus (eg, Wolcott‐Rallison syndrome) is a rare condition. It associates with neonatal or early‐infancy insulin‐dependent diabetes. We reported DKA in the four‐month infant as the first presentation of monogenic diabetes that has accelerated by COVID‐19 infection. Therefore, considering the concurrency of COVID‐19 and DKA is crucial.
- Open Access
- 27 January 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (3) , 1663-1666
Synchronous presentation of COVID‐19 pneumonia and pulmonary embolism
The patients with COVID‐19 pneumonia who suffer from worsening of the clinical respiratory symptoms, after the beginning of the treatment, should be evaluated for pulmonary embolism using CT angiography if there are no contraindications.
- 27 January 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (3) , 1663-1666
Open AccessSynchronous presentation of COVID‐19 pneumonia and pulmonary embolism
The patients with COVID‐19 pneumonia who suffer from worsening of the clinical respiratory symptoms, after the beginning of the treatment, should be evaluated for pulmonary embolism using CT angiography if there are no contraindications.
- Open Access
- 5 July 2020
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 30 (4)
A 35-Day Old Infant with COVID-19
: In late 2019, a novel coronavirus named COVID-19 led to a large outbreak in China and many other countries. A few cases of pneumonia in newborns and infants with COVID-19 infection have been reported. The neonates and infants described as the cases of COVID-19 had been asymptomatic or have had mild symptoms. The target of the current report is a 35-day-old male infant with respiratory distress and cyanosis. The chest x-ray CT images revealed manifestation of lung infection. The upper respiratory sampling was done by pharyngeal swab and the results confirmed the COVID-19 infection. Considering the positive test results and the severity of the respiratory distress, a complex medication treatment was administered. As a result, the symptoms alleviated, and the patient was discharged after complete remission on the 11th day. Although rare cases of COVID-19 infection in infants have been reported, the transmission of disease from affected persons to infants can happen. Therefore, further studies for early diagnosis and management of the COVID-19 in newborns and infants are necessary.
- 5 July 2020
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 30 (4)
Open AccessA 35-Day Old Infant with COVID-19
: In late 2019, a novel coronavirus named COVID-19 led to a large outbreak in China and many other countries. A few cases of pneumonia in newborns and infants with COVID-19 infection have been reported. The neonates and infants described as the cases of COVID-19 had been asymptomatic or have had mild symptoms. The target of the current report is a 35-day-old male infant with respiratory distress and cyanosis. The chest x-ray CT images revealed manifestation of lung infection. The upper respiratory sampling was done by pharyngeal swab and the results confirmed the COVID-19 infection. Considering the positive test results and the severity of the respiratory distress, a complex medication treatment was administered. As a result, the symptoms alleviated, and the patient was discharged after complete remission on the 11th day. Although rare cases of COVID-19 infection in infants have been reported, the transmission of disease from affected persons to infants can happen. Therefore, further studies for early diagnosis and management of the COVID-19 in newborns and infants are necessary.